Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Why is Warner Bros. Discovery splitting into two companies? How will the National Guard deployment impact LA protests? What’s driving Apple’s stock drop after WWDC event? Why did Disney pay less for full control of Hulu? How are US-China trade talks affecting markets today? What caused Sunnova Energy’s bankruptcy in solar sector? Why is Amazon investing $20 billion in Pennsylvania data centers?

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

benzinga.com/news/health-care/25/06/45844858/metsera-stock-rises-as-company-advances-obesity-pipeline-with-encouraging-weight-loss-data

Metsera, Inc. (NASDAQ:MTSR) on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera’s fully-biased monthly GLP-1 receptor agonist candidate,…

This story appeared on benzinga.com, 2025-06-09 18:07:42.